GlassScriptPhysician profile
Kayur V Patel
NPI 1831333855
$12,714.44
in general payments reported to CMS, 2019-2025
38 companies · $2,406 in 2025
The $2,406 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91.92 · 2020: $68.19 · 2021: $1,663 · 2022: $2,586 · 2023: $3,317 · 2024: $2,583 · 2025: $2,406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,218 · Education: $87.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,218.23 |
| Education | $87.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,861.64 | 2021-2025 | Krystexxa, Evenity, Tavneos |
| Abbvie INC. | $1,600.95 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,144.81 | 2021-2025 | |
| Horizon Therapeutics Plc | $1,053.80 | 2021-2023 | Krystexxa |
| Janssen Biotech, INC. | $989.86 | 2021-2025 | Simponi Aria, Tremfya, Simponi |
| Ucb, INC. | $943.91 | 2021-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $793.08 | 2021-2025 | |
| Ani Pharmaceuticals, INC. | $544.45 | 2023-2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $502.24 | 2021-2024 | Taltz |
| Glaxosmithkline, LLC. | $467.30 | 2022-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $455.05 | 2021-2024 | Evusheld, Saphnelo, Bevespi Aerosphere |
| E.R. Squibb & Sons, L.L.C. | $393.16 | 2021-2025 | Orencia |
| Hospira, INC. | $239.41 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $223.11 | 2021-2025 | Strensiq, Ultomiris |
| Mallinckrodt Hospital Products INC. | $170.90 | 2021-2024 | Acthar |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $150.69 | 2024 | Panzyga, Octagam Immune Globulin (Human) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.46 | 2021-2025 | Cyltezo, Ofev |
| Genzyme Corporation | $133.38 | 2024-2025 | |
| Genentech USA, INC. | $115.89 | 2024-2025 | Actemra |
| Organon LLC | $107.46 | 2022-2024 | Hadlima, Renflexis |
| Sandoz INC. | $94.24 | 2023-2024 | Hyrimoz |
| Sobi, INC | $84.51 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $56.43 | 2023-2025 | Entyvio, Hyqvia |
| Fresenius Kabi USA, LLC | $55.05 | 2023 | Idacio |
| Invivyd INC | $50.51 | 2025 | Pemgarda |
| Ultragenyx Pharmaceutical INC. | $50.29 | 2022-2023 | |
| Radius Health, INC. | $49.14 | 2019-2025 | Tymlos |
| Actelion Pharmaceuticals US, INC. | $30.75 | 2021 | |
| Tersera Therapeutics LLC | $30.24 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $26.78 | 2023 | Truxima |
| Bioventus LLC | $24.99 | 2024 | Supartz Fx Sodium Hyaluronate |
| Celltrion USA INC. | $23.71 | 2023 | Yuflyma |
| Orthogenrx INC. | $23.16 | 2021 | |
| Avanos Medical | $19.96 | 2023 | Genvisc 850 Sodium Hyaluronate |
| Biocon Biologics INC | $19.17 | 2023 | Hulio |
| Depuy Synthes Sales INC. | $16.80 | 2024 | Monovisc |
| Hikma Pharmaceuticals USA | $15.29 | 2021 | |
| Aurinia Pharma U.S., INC. | $11.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayur Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.